Xvivo Perfusion AB (publ)
XVIPY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.4% | -3.9% | 14.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 74.4% | 73.4% | 77% | 74.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 4% | 12.2% | 6.8% | 10.3% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$0 | $0 | $0 |
| % Margin | 0.9% | -5.7% | 16% | 43.2% |
| EPS | 0.013 | -0.098 | 0.29 | 0.68 |
| % Growth | 112.8% | -133.6% | -57.4% | – |
| EPS Diluted | 0.013 | -0.098 | 0.29 | 0.68 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 9% | 17.3% | 12.3% | 10.3% |